Mohinder Gupta, MD
Ophthalmology · Ashland, OHNPI 1629076948
Payments from drug & device makers
What this record shows
This record is dominated by other: $15,471 of the $19,974 with a category attached, or 77.5%. Johnson & Johnson Surgical Vision, Inc. accounts for 77.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $16,628 and has fallen 98.0% since, to $333 in 2025. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $161.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$15K
- Alcon$1K
- AbbVie$1K
- Biotissue Holdings Inc.$402
- Bausch & Lomb, A Division Of Bausch Health US, LLC$261
- Bausch & Lomb Americas Inc.$258
- plus $1K from 12 others
What the payments were for
- Travel & lodging$1,0985%
- Food & beverage$3,39417%
- Education$110%
- Other$15,47177%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 1 | $15,471 |
| Alcon | 69 | $1,317 |
| AbbVie(2 entities) | 11 | $1,144 |
| Biotissue Holdings Inc. | 3 | $402 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $261 |
| Bausch & Lomb Americas Inc. | 4 | $258 |
| Ivantis, Inc | 9 | $211 |
| Scpharmaceuticals Inc. | 7 | $210 |
| Dompe US, Inc. | 2 | $162 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| GSK | 1 | $125 |
| Oyster Point Pharma, Inc. | 1 | $98 |
| Sight Sciences, Inc. | 3 | $62 |
| Ocular Therapeutix, Inc. | 2 | $40 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Sun Pharmaceutical Industries Inc. | 2 | $26 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$843
- Hydrus Microstent$258
- Prokera$218
- AmnioGraft$218
- AmnioGuard$218
- EYLEA$125
- VYZULTA$125
- SHINGRIX$125
- Oxervate$124
How this compares
$19,974 in reported general payments places this provider in the 90th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 14 | $601,501 |
| MieboPerfluorohexyloctane/Pf | 42 | $35,451 |
| RestasisCyclosporine | 21 | $23,015 |
| Fluorometholone | 418 | $21,536 |
| VyzultaLatanoprostene Bunod | 23 | $11,437 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $10,698 |
| Prednisolone Acetate | 379 | $10,080 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $8,754 |
| TyrvayaVarenicline Tartrate | 14 | $8,372 |
| Loteprednol Etabonate | 49 | $5,558 |
| Ketorolac Tromethamine | 374 | $5,364 |
| Latanoprost | 433 | $3,110 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 172 | $3,057 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $2,744 |
| Timolol Maleate | 199 | $2,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $162 | $601,50114 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $258 | $46,88865 claims |
| AbbVieRestasis | $1,144 | $23,01521 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $17 | $10,69814 claims |
| AlconSimbrinza | $1,317 | $8,75422 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $98 | $8,37214 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $261 | $5,55849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Ashland
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.